{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:16:21Z","timestamp":1793301381395,"version":"4.5.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","bmn.com","clinicalkey.com","cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Biotechnology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.tibtech.2024.05.002","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:10:52Z","timestamp":1717114252000},"page":"1439-1452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Ocular RNA nanomedicine: engineered delivery nanoplatforms in treating eye diseases"],"prefix":"10.1016","volume":"42","author":[{"given":"Yiming","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad M.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4277-3728","authenticated-orcid":false,"given":"Wei","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tibtech.2024.05.002_bb0005","first-page":"0291","article-title":"AAV for gene therapy in ocular diseases: progress and prospects","volume":"6","author":"He","year":"2023","journal-title":"Research (Wash. D. C.)"},{"key":"10.1016\/j.tibtech.2024.05.002_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114770","article-title":"Polymer- and lipid-based nanocarriers for ocular drug delivery: current status and future perspectives","volume":"196","author":"Han","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0015","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s12951-022-01567-7","article-title":"Recent achievements in nano-based technologies for ocular disease diagnosis and treatment, review and update","volume":"20","author":"Afarid","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2022.101110","article-title":"RNA-targeting strategies as a platform for ocular gene therapy","volume":"92","author":"Kumar","year":"2023","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0025","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s12276-022-00757-5","article-title":"RNA therapy: rich history, various applications and unlimited future prospects","volume":"54","author":"Kim","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0030","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrd.2018.93","article-title":"Principles for targeting RNA with drug-like small molecules","volume":"17","author":"Warner","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0035","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41573-023-00704-7","article-title":"Amplifying gene expression with RNA-targeted therapeutics","volume":"22","author":"Khorkova","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0040","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2304966120","article-title":"Inhaled mRNA nanoparticles dual-targeting cancer cells and macrophages in the lung for effective transfection","volume":"120","author":"Tang","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0045","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","article-title":"mRNA-based cancer therapeutics","volume":"23","author":"Liu","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tibtech.2024.05.002_bb0050","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/s41573-022-00521-4","article-title":"Targeting RNA structures with small molecules","volume":"21","author":"Childs-Disney","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0055","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2214-109X(20)30488-5","article-title":"The Lancet Global Health Commission on Global Eye Health: vision beyond 2020","volume":"9","author":"Burton","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.tibtech.2024.05.002_bb0060","doi-asserted-by":"crossref","first-page":"7481","DOI":"10.3390\/ijms24087481","article-title":"Retinitis pigmentosa: current clinical management and emerging therapies","volume":"24","author":"Nguyen","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0065","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2112696119","article-title":"Intravesical delivery of KDM6A-mRNA via mucoadhesive nanoparticles inhibits the metastasis of bladder cancer","volume":"119","author":"Kong","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0070","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay1063","article-title":"siRNA nanoparticles targeting CaMKII\u03b3 in lesional macrophages improve atherosclerotic plaque stability in mice","volume":"12","author":"Tao","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0075","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","article-title":"Therapeutic in vivo delivery of gene editing agents","volume":"185","author":"Raguram","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.tibtech.2024.05.002_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.101029","article-title":"Inherited retinal diseases: linking genes, disease-causing variants, and relevant therapeutic modalities","volume":"89","author":"Schneider","year":"2022","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0085","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","article-title":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study","volume":"9","author":"GBD 2019 Blindness and Vision Impairment Collaborators","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.tibtech.2024.05.002_bb0090","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/d41573-018-00016-1","article-title":"Gene therapies in ophthalmic disease","volume":"18","author":"Gordon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0095","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1126\/science.aad8709","article-title":"From the RNA world to the clinic","volume":"352","author":"Sullenger","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.tibtech.2024.05.002_bb0100","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax1210","article-title":"CRISPR-Cas9-mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis","volume":"5","author":"Jo","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0105","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.exer.2018.01.009","article-title":"Express: a database of transcriptome profiles encompassing known and novel transcripts across multiple development stages in eye tissues","volume":"168","author":"Budak","year":"2018","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.100975","article-title":"Early and late stage gene therapy interventions for inherited retinal degenerations","volume":"86","author":"Botto","year":"2022","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.preteyeres.2017.03.003","article-title":"Unravelling the genetics of inherited retinal dystrophies: past, present and future","volume":"59","author":"Broadgate","year":"2017","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0120","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.ophtha.2018.12.050","article-title":"The oculome panel test: next-generation sequencing to diagnose a diverse range of genetic developmental eye disorders","volume":"126","author":"Patel","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.tibtech.2024.05.002_bb0125","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1167\/iovs.64.7.39","article-title":"Gene therapy for retinal degenerative diseases: progress, challenges, and future directions","volume":"64","author":"Drag","year":"2023","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0130","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","article-title":"C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal Phase 2\/3 trial","volume":"128","author":"Jaffe","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.tibtech.2024.05.002_bb0135","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamaophthalmol.2021.1407","article-title":"Enlargement of geographic atrophy from first diagnosis to end of life","volume":"139","author":"Colijn","year":"2021","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0140","doi-asserted-by":"crossref","first-page":"6975","DOI":"10.1021\/acs.jmedchem.2c00024","article-title":"The progress and promise of RNA medicine  an arsenal of targeted treatments","volume":"65","author":"Sasso","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0145","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1172\/JCI123353","article-title":"Circular RNA-ZNF532 regulates diabetes-induced retinal pericyte degeneration and vascular dysfunction","volume":"130","author":"Jiang","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0150","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1073\/pnas.1814874116","article-title":"Targeting pericyte\u2013endothelial cell crosstalk by circular RNA-cPWWP2A inhibition aggravates diabetes-induced microvascular dysfunction","volume":"116","author":"Liu","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0155","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.7150\/thno.19353","article-title":"Silencing of circular RNA-ZNF609 ameliorates vascular endothelial dysfunction","volume":"7","author":"Liu","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.tibtech.2024.05.002_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105698","article-title":"Adenovirus-mediated down-regulation of miR-21-5p alleviates experimental autoimmune uveoretinitis in mice","volume":"74","author":"Shi","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0165","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s43586-023-00246-7","article-title":"Nanotechnology-based mRNA vaccines","volume":"3","author":"Chen","year":"2023","journal-title":"Nat. Rev. Methods Primers"},{"key":"10.1016\/j.tibtech.2024.05.002_bb0170","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1021\/acs.accounts.1c00521","article-title":"Immunogenicity of in vitro-transcribed RNA","volume":"54","author":"Mu","year":"2021","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0175","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1021\/acs.chemrev.3c00611","article-title":"Chemically modified platforms for better RNA therapeutics","volume":"124","author":"Shi","year":"2024","journal-title":"Chem. Rev."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0180","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.7150\/thno.19374","article-title":"Discovery of aptamer ligands for hepatic stellate cells using SELEX","volume":"7","author":"Chen","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.tibtech.2024.05.002_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114342","article-title":"Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies","volume":"187","author":"Alshaikh","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0190","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12951-020-00745-9","article-title":"Distribution of polymeric nanoparticles in the eye: implications in ocular disease therapy","volume":"19","author":"Swetledge","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0195","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12951-023-01992-2","article-title":"Nanotechnology-based ocular drug delivery systems: recent advances and future prospects","volume":"21","author":"Li","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0200","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.3390\/ijms24032753","article-title":"High-capacity mesoporous silica nanocarriers of siRNA for applications in retinal delivery","volume":"24","author":"Ultimo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115082","article-title":"Microneedles for advanced ocular drug delivery","volume":"201","author":"Glover","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0210","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jconrel.2020.07.004","article-title":"Topical siRNA delivery to the cornea and anterior eye by hybrid silicon-lipid nanoparticles","volume":"326","author":"Baran-Rachwalska","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.tibtech.2024.05.002_bb0215","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/mt.2013.216","article-title":"In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma","volume":"22","author":"Mart\u00ednez","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0220","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/02713681003597230","article-title":"A siRNA targeting vascular endothelial growth factor-A inhibiting experimental corneal neovascularization","volume":"35","author":"Zuo","year":"2010","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0225","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/ICO.0b013e31802b4201","article-title":"Unique homologous siRNA blocks hypoxia-induced VEGF upregulation in human corneal cells and inhibits and regresses murine corneal neovascularization","volume":"26","author":"Singh","year":"2007","journal-title":"Cornea"},{"key":"10.1016\/j.tibtech.2024.05.002_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115116","article-title":"Nano\u2013bio interactions in mRNA nanomedicine: challenges and opportunities for targeted mRNA delivery","volume":"203","author":"Saiding","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0235","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1039\/D1CS00617G","article-title":"Emerging mRNA technologies: delivery strategies and biomedical applications","volume":"51","author":"Xiao","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0240","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0245","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jconrel.2019.04.015","article-title":"Lipid nanoparticles for delivery of messenger RNA to the back of the eye","volume":"303","author":"Patel","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.tibtech.2024.05.002_bb0250","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add4623","article-title":"Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates","volume":"9","author":"Herrera-Barrera","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0255","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.1167\/iovs.10-5891","article-title":"A lipid nanoparticle system improves siRNA efficacy in RPE cells and a laser-induced murine CNV model","volume":"52","author":"Liu","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0260","article-title":"Trimethyl chitosan-hyaluronic acid nano-polyplexes for intravitreal VEGFR-2 siRNA delivery: formulation and in vivo efficacy evaluation","volume":"26","author":"Chaharband","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.tibtech.2024.05.002_bb0265","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1021\/acs.nanolett.9b02596","article-title":"Octopus-like flexible vector for noninvasive intraocular delivery of short interfering nucleic acids","volume":"19","author":"Jiang","year":"2019","journal-title":"Nano Lett."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0270","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3390\/pharmaceutics14020243","article-title":"MicroRNA-539-5p-loaded PLGA nanoparticles grafted with iRGD as a targeting treatment for choroidal neovascularization","volume":"14","author":"Alanazi","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.tibtech.2024.05.002_bb0275","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.actbio.2021.07.053","article-title":"A core-shell nanoplatform as a nonviral vector for targeted delivery of genes to the retina","volume":"134","author":"Tan","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0280","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/mabi.201600051","article-title":"Reducible polyethylenimine nanoparticles for efficient siRNA delivery in corneal neovascularization therapy","volume":"16","author":"Han","year":"2016","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0285","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.ymthe.2020.06.029","article-title":"Gene therapy intervention in neovascular eye disease: a recent update","volume":"28","author":"Lin","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0290","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.omtn.2019.07.017","article-title":"Effective in vivo topical delivery of siRNA and gene silencing in intact corneal epithelium using a modified cell-penetrating peptide. Mol. Ther","volume":"17","author":"Schiroli","year":"2019","journal-title":"Nucleic Acids"},{"key":"10.1016\/j.tibtech.2024.05.002_bb0295","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jconrel.2021.06.030","article-title":"In vivo targeted delivery of nucleic acids and CRISPR genome editors enabled by GSH-responsive silica nanoparticles","volume":"336","author":"Wang","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.tibtech.2024.05.002_bb0300","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jconrel.2020.04.052","article-title":"A pH-responsive silica-metal-organic framework hybrid nanoparticle for the delivery of hydrophilic drugs, nucleic acids, and CRISPR-Cas9 genome-editing machineries","volume":"324","author":"Wang","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.tibtech.2024.05.002_bb0305","first-page":"1029","article-title":"Novel epithelial cell adhesion molecule antibody conjugated polyethyleneimine-capped gold nanoparticles for enhanced and targeted small interfering RNA delivery to retinoblastoma cells","volume":"19","author":"Mitra","year":"2013","journal-title":"Mol. Vis."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0310","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41551-021-00764-3","article-title":"Reduction of choroidal neovascularization via cleavable VEGF antibodies conjugated to exosomes derived from regulatory T cells","volume":"5","author":"Tian","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0315","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-023-01112-3","article-title":"Exosome-loaded degradable polymeric microcapsules for the treatment of vitreoretinal diseases","author":"Bao","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0320","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj9617","article-title":"miR-204-containing exosomes ameliorate GVHD-associated dry eye disease","volume":"8","author":"Zhou","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0325","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s41232-023-00260-y","article-title":"Accelerating corneal wound healing using exosome-mediated targeting of NF-\u03baB c-Rel","volume":"43","author":"Zhao","year":"2023","journal-title":"Inflamm. Regen."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0330","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41551-020-00656-y","article-title":"Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice","volume":"5","author":"Ling","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0335","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/bjophthalmol-2021-319067","article-title":"Three-year results of phase I retinal gene therapy trial for CNGA3-mutated achromatopsia: results of a non randomised controlled trial","volume":"106","author":"Reichel","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0340","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/medicina57010064","article-title":"Update on gene therapy clinical trials for choroideremia and potential experimental therapies","volume":"57","author":"Abbouda","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.tibtech.2024.05.002_bb0345","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jamaophthalmol.2019.3278","article-title":"Efficacy and safety of retinal gene therapy using adeno-associated virus vector for patients with choroideremia: a randomized clinical trial","volume":"137","author":"Fischer","year":"2019","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0350","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00439-016-1637-y","article-title":"Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a Phase I trial","volume":"135","author":"Ghazi","year":"2016","journal-title":"Hum. Genet."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0355","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.omtn.2017.12.019","article-title":"Transcriptome profiling of neovascularized corneas reveals miR-204 as a multi-target biotherapy deliverable by rAAVs","volume":"10","author":"Lu","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.tibtech.2024.05.002_bb0360","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1086\/519025","article-title":"RNA interference-mediated suppression and replacement of human rhodopsin in vivo","volume":"81","author":"O\u2019Reilly","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0365","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41587-020-00781-8","article-title":"Targeting herpes simplex virus with CRISPR-Cas9 cures herpetic stromal keratitis in mice","volume":"39","author":"Yin","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0370","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd3438","article-title":"Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses","volume":"13","author":"Chan","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0375","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1706910","article-title":"Gene therapy","volume":"381","author":"High","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0380","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.addr.2020.06.011","article-title":"Ocular delivery of CRISPR\/Cas genome editing components for treatment of eye diseases","volume":"168","author":"Yu","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0385","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1172\/JCI129085","article-title":"AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression","volume":"129","author":"Ding","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0390","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.gt.3302641","article-title":"Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1","volume":"13","author":"Shen","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0395","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.msec.2017.04.068","article-title":"Non-viral strategies for ocular gene delivery","volume":"77","author":"Oliveira","year":"2017","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0400","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-chembioeng-101420-014055","article-title":"RNA engineering for public health: innovations in RNA-based diagnostics and therapeutics","volume":"12","author":"Thavarajah","year":"2021","journal-title":"Annu. Rev. Chem. Biomol. Eng."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100918","article-title":"Patient derived stem cells for discovery and validation of novel pathogenic variants in inherited retinal disease","volume":"83","author":"Mullin","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0410","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.stem.2016.03.021","article-title":"Identification and correction of mechanisms underlying inherited blindness in human iPSC-derived optic cups","volume":"18","author":"Parfitt","year":"2016","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.tibtech.2024.05.002_bb0415","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/jamaophthalmol.2020.6418","article-title":"Analysis of pathogenic variants correctable with CRISPR base editing among patients with recessive inherited retinal degeneration","volume":"139","author":"Fry","year":"2021","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0420","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41467-017-00140-3","article-title":"Genome editing abrogates angiogenesis in vivo","volume":"8","author":"Huang","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0425","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1016\/j.ymthe.2023.08.021","article-title":"In vivo CRISPR gene editing in patients with herpetic stromal keratitis","volume":"31","author":"Wei","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0430","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188899","article-title":"First-in-human Phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-\u03b22), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery","volume":"12","author":"Pfeiffer","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.tibtech.2024.05.002_bb0435","first-page":"3023","article-title":"Results of Phase IIB SYLTAG clinical trial with bamosiran in patients with glaucoma","volume":"57","author":"Gonzalez","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0440","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/s41591-022-01755-w","article-title":"Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a Phase 1b\/2 trial","volume":"28","author":"Russell","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0445","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat5580","article-title":"Clinical-grade stem cell-derived retinal pigment epithelium patch rescues retinal degeneration in rodents and pigs","volume":"11","author":"Sharma","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0450","first-page":"3062","article-title":"Injectable bio-responsive hydrogel for therapy of inflammation related eyelid diseases","volume":"6","author":"Chen","year":"2021","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0455","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1038\/s41467-021-25181-7","article-title":"GLIS1 regulates trabecular meshwork function and intraocular pressure and is associated with glaucoma in humans","volume":"12","author":"Nair","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119935","article-title":"Sustained delivery of acriflavine from the suprachoroidal space provides long term suppression of choroidal neovascularization","volume":"243","author":"Hackett","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.tibtech.2024.05.002_bb0465","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.it.2017.11.007","article-title":"When clarity is crucial: regulating ocular surface immunity","volume":"39","author":"Foulsham","year":"2018","journal-title":"Trends Immunol."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0470","doi-asserted-by":"crossref","first-page":"507","DOI":"10.7150\/ijbs.30575","article-title":"Autophagy resists EMT process to maintain retinal pigment epithelium homeostasis","volume":"15","author":"Feng","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.tibtech.2024.05.002_bb0475","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/s41433-022-02154-8","article-title":"Personalized treatment supported by automated quantitative fluid analysis in active neovascular age-related macular degeneration (nAMD) \u2013 a Phase III, prospective, multicentre, randomized study: design and methods","volume":"37","author":"Coulibaly","year":"2023","journal-title":"Eye"},{"key":"10.1016\/j.tibtech.2024.05.002_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2019.100779","article-title":"Retinal stem cell transplantation: balancing safety and potential","volume":"75","author":"Singh","year":"2020","journal-title":"Prog. Retin. Eye Res."}],"container-title":["Trends in Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167779924001215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167779924001215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T20:22:40Z","timestamp":1732306960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167779924001215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":96,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0167779924001215"],"URL":"https:\/\/doi.org\/10.1016\/j.tibtech.2024.05.002","relation":{},"ISSN":["0167-7799"],"issn-type":[{"value":"0167-7799","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular RNA nanomedicine: engineered delivery nanoplatforms in treating eye diseases","name":"articletitle","label":"Article Title"},{"value":"Trends in Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tibtech.2024.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}